In colorectal cancer, these include KRAS and NRAS mutation testing for prediction of resistance to anti-EGFR therapies,25 and MSI, which identifies stage II tumours with excellent prognosis26 and stage IV tumours likely to respond to immune checkpoint inhibition. The gene discussed is EGFR; the disease is neoplasm.